Opioid Withdrawal Syndrome Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, Therapies, Mechanism of Action, Route of Administration, and Developments | Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Braeburn Pharmaceuticals, Indivior

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Opioid Withdrawal Syndrome pipeline constitutes 4+ key companies continuously working towards developing 4+ Opioid Withdrawal Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Opioid Withdrawal Syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Opioid Withdrawal Syndrome Market.

The Opioid Withdrawal Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Opioid Withdrawal Syndrome Pipeline Report: https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Opioid Withdrawal Syndrome treatment therapies with a considerable amount of success over the years.
• Opioid Withdrawal Syndrome companies working in the treatment market are Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Braeburn Pharmaceuticals, Indivior, and others, are developing therapies for the Opioid Withdrawal Syndrome treatment
• Emerging Opioid Withdrawal Syndrome therapies in the different phases of clinical trials are- CHF-6563, BXCL501, BRIXADI (buprenorphine), SUBLOCADE (buprenorphine), CAM2038, and others are expected to have a significant impact on the Opioid Withdrawal Syndrome market in the coming years.
• In October 2024, ANANDA Scientific Inc., a biopharmaceutical company focused on research, today announced the initiation of a clinical trial to evaluate Nantheia™ ATL5. This investigational drug combines cannabidol with ANANDA's proprietary delivery technology and is co-administered with delta-9-tetrahydrocannabinol (THC). The trial aims to assess its potential effectiveness in treating co-occurring opioid use disorder (OUD) and chronic pain. (Clinical Trials.gov Identifier: NCT06544291)

Opioid Withdrawal Syndrome Overview
Opioid Withdrawal Syndrome is a condition that occurs when individuals who are dependent on opioids abruptly reduce or stop their use. It results from the body's adaptation to prolonged opioid use, leading to physical dependence. Symptoms of withdrawal can range from mild to severe and typically include anxiety, agitation, muscle aches, sweating, nausea, vomiting, diarrhea, and insomnia. While the syndrome itself is not life-threatening, it can be extremely uncomfortable and may lead to relapse if not managed properly. Treatment often includes supportive care, medications like buprenorphine or methadone, and behavioral therapy to aid recovery.

Get a Free Sample PDF Report to know more about Opioid Withdrawal Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/opioid-withdrawal-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Opioid Withdrawal Syndrome Drugs Under Different Phases of Clinical Development Include:
• CHF-6563: Chiesi Farmaceutici S.p.A.
• BXCL501: BioXcel Therapeutics
• BRIXADI (buprenorphine): Braeburn Pharmaceuticals
• SUBLOCADE (buprenorphine): Indivior
• CAM2038: Braeburn Pharmaceuticals

Opioid Withdrawal Syndrome Route of Administration
Opioid Withdrawal Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Opioid Withdrawal Syndrome Molecule Type
Opioid Withdrawal Syndrome Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Opioid Withdrawal Syndrome Pipeline Therapeutics Assessment
• Opioid Withdrawal Syndrome Assessment by Product Type
• Opioid Withdrawal Syndrome By Stage and Product Type
• Opioid Withdrawal Syndrome Assessment by Route of Administration
• Opioid Withdrawal Syndrome By Stage and Route of Administration
• Opioid Withdrawal Syndrome Assessment by Molecule Type
• Opioid Withdrawal Syndrome by Stage and Molecule Type

DelveInsight's Opioid Withdrawal Syndrome Report covers around 4+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Opioid Withdrawal Syndrome product details are provided in the report. Download the Opioid Withdrawal Syndrome pipeline report to learn more about the emerging Opioid Withdrawal Syndrome therapies at:
https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Opioid Withdrawal Syndrome Therapeutics Market include:
Key companies developing therapies for Opioid Withdrawal Syndrome are - Novartis, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals, MediciNova, Alkermes, Inc., Trevena, Aphios, Kyowa kirin, Gamida-Cell, BioDelivery Sciences International, Inc., and others.

Opioid Withdrawal Syndrome Pipeline Analysis:
The Opioid Withdrawal Syndrome pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Opioid Withdrawal Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Opioid Withdrawal Syndrome Treatment.
• Opioid Withdrawal Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Opioid Withdrawal Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Opioid Withdrawal Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Opioid Withdrawal Syndrome drugs and therapies-
https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Opioid Withdrawal Syndrome Pipeline Market Drivers
• Rising Prevalence of Opioid Addiction, Awareness Programs, Advancements in Treatments, Supportive Regulations, Integration of Telemedicine, are some of the important factors that are fueling the Opioid Withdrawal Syndrome Market.

Opioid Withdrawal Syndrome Pipeline Market Barriers
• However, Stigma Associated with Addiction, High Treatment Costs, Limited Access in Rural Areas, Regulatory Challenges, and other factors are creating obstacles in the Opioid Withdrawal Syndrome Market growth.

Scope of Opioid Withdrawal Syndrome Pipeline Drug Insight
• Coverage: Global
• Key Opioid Withdrawal Syndrome Companies: Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Braeburn Pharmaceuticals, Indivior, and others
• Key Opioid Withdrawal Syndrome Therapies: CHF-6563, BXCL501, BRIXADI (buprenorphine), SUBLOCADE (buprenorphine), CAM2038, and others
• Opioid Withdrawal Syndrome Therapeutic Assessment: Opioid Withdrawal Syndrome current marketed and Opioid Withdrawal Syndrome emerging therapies
• Opioid Withdrawal Syndrome Market Dynamics: Opioid Withdrawal Syndrome market drivers and Opioid Withdrawal Syndrome market barriers

Request for Sample PDF Report for Opioid Withdrawal Syndrome Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Opioid Withdrawal Syndrome Report Introduction
2. Opioid Withdrawal Syndrome Executive Summary
3. Opioid Withdrawal Syndrome Overview
4. Opioid Withdrawal Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Opioid Withdrawal Syndrome Pipeline Therapeutics
6. Opioid Withdrawal Syndrome Late Stage Products (Phase II/III)
7. Opioid Withdrawal Syndrome Mid Stage Products (Phase II)
8. Opioid Withdrawal Syndrome Early Stage Products (Phase I)
9. Opioid Withdrawal Syndrome Preclinical Stage Products
10. Opioid Withdrawal Syndrome Therapeutics Assessment
11. Opioid Withdrawal Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Opioid Withdrawal Syndrome Key Companies
14. Opioid Withdrawal Syndrome Key Products
15. Opioid Withdrawal Syndrome Unmet Needs
16 . Opioid Withdrawal Syndrome Market Drivers and Barriers
17. Opioid Withdrawal Syndrome Future Perspectives and Conclusion
18. Opioid Withdrawal Syndrome Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Opioid Withdrawal Syndrome Market https://www.delveinsight.com/report-store/opioid-withdrawal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Opioid Withdrawal Syndrome Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Opioid Withdrawal Syndrome Epidemiology https://www.delveinsight.com/report-store/opioid-withdrawal-syndrome-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Opioid Withdrawal Syndrome Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Pd-1 & Pdl1 Market: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Cervical Dysplasia Market: https://www.delveinsight.com/report-store/cervical-dysplasia-market-insights
• Hypogonadism Market: https://www.delveinsight.com/report-store/hypogonadism-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Non-hodgkin's Lymphoma Market: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-market
• Substance Use Disorder Market: https://www.delveinsight.com/report-store/substance-use-disorder-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.